These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 10905057

  • 1. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
    Fukuhara T, Miyake T, Maekawa I, Kurosawa M, Suzuki S, Noto S, Mori A, Chiba K, Toyoshima T, Hirano T, Morioka M, Tsutsumi Y, Okabe M, Kakinoki Y.
    Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
    [Abstract] [Full Text] [Related]

  • 2. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [Abstract] [Full Text] [Related]

  • 3. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH, Kantarjian HM, O'Brien S, Kornblau S, Andreeff M, Beran M, Pierce S, Keating M.
    Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
    [Abstract] [Full Text] [Related]

  • 4. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
    Saito K, Nakamura Y, Aoyagi M, Waga K, Yamamoto K, Aoyagi A, Inoue F, Nakamura Y, Arai Y, Tadokoro J, Handa T, Tsurumi S, Arai H, Kawagoe Y, Gunnji H, Kitsukawa Y, Takahashi W, Furusawa S.
    Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
    [Abstract] [Full Text] [Related]

  • 5. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J, Shao ZH, Liu H, Bai J, Cao YR, He GS, Tu MF, Wang XL, Hao YS, Yang TY, Yang CL.
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R, Pecci A, Rossi G, Pelizzari AM, Giusto M, Tinelli C, Ascari E.
    Haematologica; 1997 Jul; 82(6):660-3. PubMed ID: 9499664
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R, Pecci A, Rossi G, Pelizzari AM, Giusto M, Tinelli C, Ascari E.
    Haematologica; 1997 Jul; 82(5 Suppl):9-12. PubMed ID: 9402747
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X, Mei C, Zhang J, Lu Y, Lan J, Lin S, Zhang Y, Kuang Y, Ren Y, Ma L, Wei J, Ye L, Xu W, Li K, Lu C, Jin J, Tong H.
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [Abstract] [Full Text] [Related]

  • 13. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.
    Mori T, Aisa Y, Yokoyama A, Nakazato T, Yamazaki R, Shimizu T, Mihara A, Kato J, Watanabe R, Takayama N, Ikeda Y, Okamoto S.
    Bone Marrow Transplant; 2007 Feb; 39(4):217-21. PubMed ID: 17220902
    [Abstract] [Full Text] [Related]

  • 14. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group.
    Zwierzina H, Suciu S, Loeffler-Ragg J, Neuwirtova R, Fenaux P, Beksac M, Harousseau J, Nuessler V, Cermak J, Solbu G, Willemze R, de Witte T, Amadori S, EORTC Leukemia Cooperative Group.
    Leukemia; 2005 Nov; 19(11):1929-33. PubMed ID: 16151466
    [Abstract] [Full Text] [Related]

  • 15. [Successful treatment of acute non-lymphoblastic leukemia from myelodysplastic syndrome by combination of human macrophage colony-stimulating factor (M-CSF) and low dose cytosine arabinoside: M-CSF-induced proliferation and tyrosine phosphorylation in leukemic blasts].
    Hagiwara S, Yuo A, Nagai M, Takezako N, Soda Y, Miwa A, Togawa A, Takaku F.
    Rinsho Ketsueki; 1996 Nov; 37(11):1259-64. PubMed ID: 8960658
    [Abstract] [Full Text] [Related]

  • 16. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P, Sanpaolo G, D'Arena G, Scalzulli PR, Matera R, Falcone A, Bodenizza C, Perla G, Carotenuto M.
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [Abstract] [Full Text] [Related]

  • 17. [Study on the transformation from myelodysplastic syndromes into acute leukemias].
    Shi J, Shao Z, Liu H, Li K, Song L, Zhang Y, Zheng Y, Chen G, Chu Y, He H, Zhao M, He G, Feng B, Hao Y, Yang T, Yang C.
    Zhonghua Xue Ye Xue Za Zhi; 2001 Jul; 22(7):351-4. PubMed ID: 11877096
    [Abstract] [Full Text] [Related]

  • 18. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E, Rossi E, Clavio M, Congiu A, Gobbi M, Grosso M, Secondo V, Spriano M, Timitilli S, Ghio R.
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [Abstract] [Full Text] [Related]

  • 19. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C, Zahner J, Sayer HG.
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
    [Abstract] [Full Text] [Related]

  • 20. [Trial of combined cytosine arabinoside with granulocyte colony-stimulating factor therapy or refractory acute myeloid leukemia].
    Mori H, Kuriyama K, Tawara M, Danno Y, Fujimoto K, Tushima H, Saito M, Yamamura M, Hata T, Arimura M.
    Rinsho Ketsueki; 1995 Jul; 36(7):648-56. PubMed ID: 7563592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.